A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Dose of 800-mg Vandetanib (CAPRELSA).
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Midazolam (Primary) ; Vandetanib (Primary)
- Indications Anxiety disorders; Biliary cancer; Breast cancer; Insomnia; Prostate cancer; Sleep disorders; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Sanofi
- 26 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.